Search for author "Ron Simon"
75 Results
- Figure.You have accessNascent Proteomes in Peripheral Blood Mononuclear Cells as a Novel Source for Biomarker Discovery in Human StrokeFang Bian, Roger P. Simon, Yun Li, Larry David, Jolita Wainwright, Casey L. Hall, Michael Frankel, An ZhouStroke April 2014, 45 (4) 1177-1179; DOI: https://doi.org/10.1161/STROKEAHA.113.004576Differences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of ov...Show MoreDifferences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of overlapping of identified proteins between control (Ctr) and stroke (Str) groups (A and C, total and nascent proteomes, respectively). Numbers are the number of proteins identified by mass spectrometry. Heat maps present results of hierarchical clustering analysis, showing distances among 4 study groups in PBMC total (B) or nascent (D) proteomes. Color codes in heat maps: red and green—low and high protein abundances, respectively; gray—no protein identification. F indicates female; and M, male.Show Less
- Figure.You have accessNascent Proteomes in Peripheral Blood Mononuclear Cells as a Novel Source for Biomarker Discovery in Human StrokeFang Bian, Roger P. Simon, Yun Li, Larry David, Jolita Wainwright, Casey L. Hall, Michael Frankel, An ZhouStroke April 2014, 45 (4) 1177-1179; DOI: https://doi.org/10.1161/STROKEAHA.113.004576Differences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of ov...Show MoreDifferences in peripheral blood mononuclear cell (PBMC) proteomes. Venn diagrams illustrate the extent of overlapping of identified proteins between control (Ctr) and stroke (Str) groups (A and C, total and nascent proteomes, respectively). Numbers are the number of proteins identified by mass spectrometry. Heat maps present results of hierarchical clustering analysis, showing distances among 4 study groups in PBMC total (B) or nascent (D) proteomes. Color codes in heat maps: red and green—low and high protein abundances, respectively; gray—no protein identification. F indicates female; and M, male.Show Less
- Figure.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by...Show MoreGood clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.Show Less
- Table 1.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
- Table 2.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
- Table 3.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Postmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Bi...Show MorePostmatch Results for Women, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
- Table 4.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Postmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birm...Show MorePostmatch Results for Men, by Race for the Combined National Institute of Neurological Disorders and Stroke, Tulane, and University of Alabama at Birmingham CohortShow Less
- Figure.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116Good clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by...Show MoreGood clinical outcome at 90 days for National Institute of Neurological Disorders and Stroke (NINDS) race-by-sex subgroups relative to the pPREDICTS natural history model of acute ischemic stroke. The pPREDICTS outcome model shows percentage of subjects achieving modified Rankin Score (mRS) ≤2 based on baseline NIHSS and age. The NINDS subgroup results are superimposed on the model at the corresponding baseline NIHSS and age. Placebo outcomes were close to the predicted model for all subgroups (proximity of the control results to the middle outcome surface). Significant improvement with recombinant tissue-type plasminogen activator (rtPA) was seen for both white sexes (A; both rtPA outcomes are above the P=0.05 interval). Black men showed improvement with rtPA that was only slightly below the P=0.05 interval. However, there was no improvement for black women (arrow; B). Although the percentage that achieved an mRS of 0–2 was higher in the rtPA-treated black women group, this increase can be accounted for by baseline imbalance that favored better outcomes. NIHSS indicates National Institutes of Health Stroke Scale.Show Less
- Table 1.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
- Table 2.You have accessExplicit Consideration of Baseline Factors to Assess Recombinant Tissue-Type Plasminogen Activator Response With Respect to Race and SexPitchaiah Mandava, Santosh B. Murthy, Melody Munoz, Dawn McGuire, Roger P. Simon, Andrei V. Alexandrov, Karen C. Albright, Amelia K. Boehme, Sheryl Martin-Schild, Sharyl Martini, Thomas A. KentStroke June 2013, 44 (6) 1525-1531; DOI: https://doi.org/10.1161/STROKEAHA.113.001116
Pages
Journal
Source
- Circulation 1
- Stroke 74
Article Type
Article Type
- Acute Cerebral Infarction 21
- Acute Stroke Syndromes 1
- Acute coronary syndromes 5
- Animal models of human disease 10
- Article 10
- Basic Science Advances for Clinicians 8
- Brief Report 1
- Brief Reports 1
- Brief Reports Brief Report Brief Reports 1
- Cerebrovascular disease/stroke 6
- Clinical Investigation and Reports 1
- Clinical Sciences 10
- Genetics of Stroke 4
- Genomics of Ischemia: Introduction 12
- Glutamate-Independent Calcium Toxicity: Introduction 8
- Ischemic biology - basic studies 10
- Neuroprotectors 10
- Original Contribution 11
- Original Contributions 11
- Original Contributions Original Contribution Original Contributions 6
- Original Contributions Original Contribution Original Contributions Clinical Sciences 5
- Original Contributions; Basic Sciences 12
- Other Stroke 2
- Other diagnostic testing 1
- Thrombolysis 5
- Transient Ischemic Attacks 4
Subject
Subject
- Acute Cerebral Infarction 42
- Acute Stroke Syndromes 2
- Acute coronary syndromes 11
- Animal models of human disease 20
- CV surgery: coronary artery disease 1
- Catheter-based coronary interventions: stents 1
- Cerebrovascular disease/stroke 12
- Chronic ischemic heart disease 1
- Genetics of Stroke 8
- Ischemic biology - basic studies 20
- Neuroprotectors 20
- Other Stroke 4
- Other diagnostic testing 2
- Thrombolysis 10
- Transient Ischemic Attacks 8

